Camizestrant Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated: May 7, 2026

The clinical evidence base for Camizestrant comprises 2 peer-reviewed publications across 2 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Breast Neoplasms. Most recent publication: CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer., Future Oncol, 2025.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper.
Illuzzi G, Staniszewska AD, Gill SJ, et al. · Clin Cancer Res · 2022
PubMed: PMID 35929986 · NCT04644068 (PETRA) · Breast Neoplasms
CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer.
Hamilton EP, Loibl S, Bachelot T, et al. · Future Oncol · 2025
PubMed: PMID 40017004 · NCT05952557 (CAMBRIA-2) · Breast Neoplasms

Publications by year

2022–2025: 2 publications.

2022

2025

Publications by indication

Breast Neoplasms (2)

CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer.
Future Oncol · 2025 · PMID 40017004 · NCT05952557
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper.
Clin Cancer Res · 2022 · PMID 35929986 · NCT04644068

Publications by journal

Clin Cancer Res1 paper
Future Oncol1 paper

All Camizestrant publications (2)

2025 (1 paper)

CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer.
Hamilton EP, Loibl S, Bachelot T, et al. · Future Oncol · 2025 · Derived
PubMed: PMID 40017004 · NCT05952557 (CAMBRIA-2) · Breast Neoplasms

2022 (1 paper)

Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper.
Illuzzi G, Staniszewska AD, Gill SJ, et al. · Clin Cancer Res · 2022 · Derived
PubMed: PMID 35929986 · NCT04644068 (PETRA) · Breast Neoplasms

Sources and methodology

Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
Data freshness: Thu, 07 May 2026 20:11:22 GMT.

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).